Humana (NYSE:HUM) Issues Earnings Results

Humana (NYSE:HUM - Get Free Report) issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51, Zacks reports. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company's revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $7.23 earnings per share.

Humana Price Performance

Shares of NYSE HUM traded up $1.11 during mid-day trading on Wednesday, hitting $252.88. 208,536 shares of the stock traded hands, compared to its average volume of 1,743,589. The company has a market cap of $30.52 billion, a PE ratio of 25.38, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a 50 day simple moving average of $266.02 and a two-hundred day simple moving average of $270.56.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Truist Financial upped their target price on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research report on Friday, April 11th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. StockNews.com cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Robert W. Baird upped their price target on shares of Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Finally, Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Eighteen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Humana presently has an average rating of "Hold" and an average price target of $287.76.

Hedge Funds Weigh In On Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC acquired a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 798 shares of the insurance provider's stock, valued at approximately $202,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.